Tibet Duo Rui Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of chemical preparations, intermediates and active pharmaceutical ingredients. The Company mainly has self-produced products such as Sodium Acetate Ringer Injection and agent products such as Amoxicillin Sodium and Clavulanate Potassium for Injection. The Company's products mainly include liquid therapy, emergency medication, pediatric medication, psychiatric medication, and analgesic medication. The Company mainly operates its businesses in the domestic market.

Employees

461

Sector

Pharmaceuticals

Calendar

26/08 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
07/26/07	CN¥55.47	-0.41%	11,31,800
06/26/06	CN¥55.70	+0.20%	11,45,700
05/26/05	CN¥55.59	+3.27%	12,08,439
04/26/04	CN¥53.83	+5.78%	22,43,100
03/26/03	CN¥50.89	+2.15%	23,08,700

End-of-day quote Shenzhen S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Shenzhen S.E. Other stock markets 07/08/2026			5-day change	1st Jan Change
55.47 ^CNY	-0.41%		+11.34%	-7.04%

28/04	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
23/04	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	437.97Cr 65Cr 56Cr 52Cr 48Cr 90Cr 6.18TCr 92Cr 615.05Cr 241.41Cr 3.1TCr 243.7Cr 238.37Cr 10TCr	P/E 2024	-22.7x	P/E 2025	-46.3x
Enterprise Value	470.64Cr 70Cr 60Cr 56Cr 52Cr 97Cr 6.64TCr 99Cr 660.93Cr 259.41Cr 3.33TCr 261.88Cr 256.15Cr 11TCr	EV / Sales 2024	6.46x	EV / Sales 2025	32.7x
Free-Float	30.57%	Yield 2024 *	-	Yield 2025	-

28/04	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
23/04	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
23/04	Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Hubei Hairuidi Pharmaceutical Co., Ltd from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 2.4 million.	CI
23/04	Tibet Jiakang TImes Technology Development Co., Ltd. entered into an Equity Transfer Agreement to acquire 69% stake in Xiamen Ruitilian Pharmaceutical Technology Co., Ltd. from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 27.6 million.	CI
23/04	Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Wuhan Duorui Industrial Co., Ltd from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 5.1 million.	CI
27/02	Wang Qingtai and Cao Xiaobing completed the acquisition of an additional 24.30% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Tibet Jiakang TImes Technology Development Co., Ltd.	CI
24/02	Trading in Tibet Duo Rui Pharmaceutical's shares to halt	RE
21/01	Wang Qingtai and Cao Xiaobing proposed to acquire additional 24.30% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Tibet Jiakang TImes Technology Development Co., Ltd. for approximately CNY 620 million.	CI
05/12	Wang Qingtai, Cui Zihao and Cao Xiaobing completed the acquisition of 29.99% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Zhoushan Qingchang Enterprise Management Partnership Enterprise (Limited Partnership) and Tibet Jiakang TImes Technology Development Co., Ltd.	CI
23/25/23	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
13/25/13	Wang Qingtai, Cui Zihao and Cao Xiaobing signed an share transfer agreement to acquire 29.99% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Zhoushan Qingchang Enterprise Management Partnership Enterprise (Limited Partnership) and Tibet Jiakang TImes Technology Development Co., Ltd. for approximately CNY 760 million.	CI
29/25/29	Duorui Pharma Expects Control Change Amid Parents' Plan	MT
29/25/29	Certain A Shares of Tibet Duo Rui Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 29-SEP-2025.	CI

1 day	-0.41%
1 week	+11.34%
Current month	+11.34%
1 month	-7.58%
3 months	-34.69%
6 months	-10.08%
Current year	-7.04%

Tibet Duo Rui Pharmaceutical Co., Ltd. Share Price

Stocks

301075

CNE100004RW5

Pharmaceuticals

Valuation: Tibet Duo Rui Pharmaceutical Co., Ltd.

Chart: Tibet Duo Rui Pharmaceutical Co., Ltd.

Latest news : Tibet Duo Rui Pharmaceutical Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Tibet Duo Rui Pharmaceutical Co., Ltd.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	48.67	56.64
1 month	44.55	66.68
Current year	44.55	98.29
1 year	34.2	98.29
3 years	12.6	98.29
5 years	12.6	98.29
10 years	12.6	98.29

Manager	Title	Age	Since
Yong Deng CEO	Chief Executive Officer	60	01/12/2018
Chao Li DFI	Director of Finance/CFO	47	01/05/2017
Fen Jin DFI	Director of Finance/CFO	46	01/12/2017

Director	Title	Age	Since
Yong Deng CHM	Chairman	60	01/12/2017
Shao Zhong Zhang BRD	Director/Board Member	70	21/02/2020
Qin Deng BRD	Director/Board Member	58	21/02/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TIBET DUO RUI PHARMACEUTICAL CO., LTD.	-0.41%	+11.34%	+52.64%	+117.19%	65Cr
ELI LILLY AND COMPANY	-0.52%	+3.21%	+89.52%	+127.32%	1,05700Cr
JOHNSON & JOHNSON	+0.88%	+1.13%	+49.56%	+49.69%	62TCr
ABBVIE INC.	+0.89%	-1.95%	+24.23%	+64.44%	43TCr
ROCHE HOLDING AG	+0.71%	+3.87%	+49.07%	+37.85%	36TCr
NOVARTIS AG	+0.64%	-0.49%	+33.94%	+40.01%	30TCr
ASTRAZENECA PLC	+0.39%	-5.83%	+8.92%	+7.85%	25TCr
AMGEN INC.	+1.51%	+6.69%	+42.58%	+57.57%	22TCr
NOVO NORDISK A/S	+3.92%	-0.46%	-5.56%	-52.32%	21TCr
GILEAD SCIENCES, INC.	+1.80%	+2.30%	+11.56%	+66.35%	17TCr
Average	+0.98%	+1.68%	+35.64%	+51.60%	36.21TCr
Weighted average by Cap.	+0.66%	+1.22%	+48.72%	+64.64%

	2024	2025
Net sales	24Cr 3.57Cr 3.08Cr 2.88Cr 2.64Cr 4.97Cr 339.34Cr 5.05Cr 34Cr 13Cr 170.09Cr 13Cr 13Cr 562.3Cr	15Cr 2.28Cr 1.98Cr 1.85Cr 1.69Cr 3.18Cr 217.43Cr 3.23Cr 22Cr 8.5Cr 108.98Cr 8.58Cr 8.39Cr 360.28Cr
Net income	-6.27Cr -92.86L -80.32L -75.01L -68.81L -1.29Cr -88Cr -1.31Cr -8.8Cr -3.45Cr -44Cr -3.49Cr -3.41Cr -146.44Cr	-10Cr -1.51Cr -1.31Cr -1.22Cr -1.12Cr -2.11Cr -144.08Cr -2.14Cr -14Cr -5.63Cr -72Cr -5.69Cr -5.56Cr -238.75Cr
Net Debt	13Cr 2Cr 1.73Cr 1.61Cr 1.48Cr 2.78Cr 189.94Cr 2.83Cr 19Cr 7.42Cr 95Cr 7.49Cr 7.33Cr 314.74Cr	33Cr 4.84Cr 4.19Cr 3.91Cr 3.59Cr 6.75Cr 460.78Cr 6.86Cr 46Cr 18Cr 230.96Cr 18Cr 18Cr 763.53Cr